BUSINESS

Sanwa Kagaku Says Kumamoto Plant Remains Shut, Drug Supplies Stable

July 31, 2026

Sanwa Kagaku Kenkyusho said on July 30 that its manufacturing plant in Uto, Kumamoto Prefecture, remains out of operation after sustaining damage to buildings and production equipment in the massive earthquake that struck southwestern Japan on July 28.

The drug maker said inspections are continuing and that it will announce a production restart timeline once it has been determined.

They added that inventories are sufficient to prevent any immediate supply disruptions. If prolonged restoration work is expected to affect supplies, the company said it will promptly disclose the situation.

Related Article

BUSINESS

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

By Ken Yoshino

Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…

By Philip Carrigan

We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…